Update on Epithelial-Mesenchymal Plasticity in Cancer Progression

Overview

Journal Annu Rev Pathol

Publisher Annual Reviews

Specialty Pathology

Date 2023 Sep 27

PMID 37758242

Authors

Rosa Fontana

Aida Mestre-Farrera

Jing Yang

Affiliations

Soon will be listed here.

Abstract

Epithelial-mesenchymal transition (EMT) is a cellular process by which epithelial cells lose their characteristics and acquire mesenchymal traits to promote cell movement. This program is aberrantly activated in human cancers and endows tumor cells with increased abilities in tumor initiation, cell migration, invasion, metastasis, and therapy resistance. The EMT program in tumors is rarely binary and often leads to a series of gradual or intermediate epithelial-mesenchymal states. Functionally, epithelial-mesenchymal plasticity (EMP) improves the fitness of cancer cells during tumor progression and in response to therapies. Here, we discuss the most recent advances in our understanding of the diverse roles of EMP in tumor initiation, progression, metastasis, and therapy resistance and address major clinical challenges due to EMP-driven phenotypic heterogeneity in cancer. Uncovering novel molecular markers and key regulators of EMP in cancer will aid the development of new therapeutic strategies to prevent cancer recurrence and overcome therapy resistance.

Citing Articles

tailored confining microenvironment for lung cancer spheroids.

Dong Y, Qian S, Wang X, Zhang W, Lu W, Qu J Mater Today Bio. 2025; 31:101602.

PMID: 40070872 PMC: 11894329. DOI: 10.1016/j.mtbio.2025.101602.

Deubiquitinase USP28 promotes the malignant progression and radio-resistance of hepatocellular carcinoma by stabilizing WDHD1.

Wen W, Zhou Z, Chen C, Chen M Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39928151 DOI: 10.1007/s00210-025-03793-w.

USP1 promotes pancreatic cancer progression and autophagy by deubiquitinating ATG14.

Li L, Fan Z, Liu M, Dong H, Li J, Li Y J Biol Chem. 2025; 301(3):108190.

PMID: 39814232 PMC: 11871461. DOI: 10.1016/j.jbc.2025.108190.

SH2D5 promotes lung adenocarcinoma cell metastasis and triggers EMT via activating AKT signaling pathway.

Du L, Ren W, Liu L, Zhu H, Xu K, Zhou Y PLoS One. 2025; 19(12):e0316432.

PMID: 39775732 PMC: 11684657. DOI: 10.1371/journal.pone.0316432.

Fusobacterium nucleatum promotes colorectal cancer liver metastasis via miR-5692a/IL-8 axis by inducing epithelial-mesenchymal transition.

Yu Y, Yin H, Wu B, Zhao W, Wang Y, Aili A J Biomed Sci. 2025; 32(1):5.

PMID: 39757156 PMC: 11702224. DOI: 10.1186/s12929-024-01097-4.

References

Escriva M, Peiro S, Herranz N, Villagrasa P, Dave N, Montserrat-Sentis B . Repression of PTEN phosphatase by Snail1 transcriptional factor during gamma radiation-induced apoptosis. Mol Cell Biol. 2008; 28(5):1528-40. PMC: 2258777. DOI: 10.1128/MCB.02061-07. View

Ju S, Wang F, Wang Y, Ju S . CSN8 is a key regulator in hypoxia-induced epithelial-mesenchymal transition and dormancy of colorectal cancer cells. Mol Cancer. 2020; 19(1):168. PMC: 7708218. DOI: 10.1186/s12943-020-01285-4. View

Kallergi G, Papadaki M, Politaki E, Mavroudis D, Georgoulias V, Agelaki S . Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. Breast Cancer Res. 2011; 13(3):R59. PMC: 3218948. DOI: 10.1186/bcr2896. View

Strauss R, Li Z, Liu Y, Beyer I, Persson J, Sova P . Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticity. PLoS One. 2011; 6(1):e16186. PMC: 3021543. DOI: 10.1371/journal.pone.0016186. View

Li N, Babaei-Jadidi R, Lorenzi F, Spencer-Dene B, Clarke P, Domingo E . An FBXW7-ZEB2 axis links EMT and tumour microenvironment to promote colorectal cancer stem cells and chemoresistance. Oncogenesis. 2019; 8(3):13. PMC: 6381143. DOI: 10.1038/s41389-019-0125-3. View

Wei S, Fattet L, Tsai J, Guo Y, Pai V, Majeski H . Matrix stiffness drives epithelial-mesenchymal transition and tumour metastasis through a TWIST1-G3BP2 mechanotransduction pathway. Nat Cell Biol. 2015; 17(5):678-88. PMC: 4452027. DOI: 10.1038/ncb3157. View

Aceto N, Bardia A, Miyamoto D, Donaldson M, Wittner B, Spencer J . Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014; 158(5):1110-1122. PMC: 4149753. DOI: 10.1016/j.cell.2014.07.013. View

Korpal M, Ell B, Buffa F, Ibrahim T, Blanco M, Celia-Terrassa T . Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat Med. 2011; 17(9):1101-8. PMC: 3169707. DOI: 10.1038/nm.2401. View

Wu Y, Ginther C, Kim J, Mosher N, Chung S, Slamon D . Expression of Wnt3 activates Wnt/β-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells. Mol Cancer Res. 2012; 10(12):1597-606. PMC: 3732195. DOI: 10.1158/1541-7786.MCR-12-0155-T. View

10.

Ocana O, Corcoles R, Fabra A, Moreno-Bueno G, Acloque H, Vega S . Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell. 2012; 22(6):709-24. DOI: 10.1016/j.ccr.2012.10.012. View

11.

Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. PMC: 2728032. DOI: 10.1016/j.cell.2008.03.027. View

12.

Pastushenko I, Mauri F, Song Y, de Cock F, Meeusen B, Swedlund B . Fat1 deletion promotes hybrid EMT state, tumour stemness and metastasis. Nature. 2020; 589(7842):448-455. PMC: 7612440. DOI: 10.1038/s41586-020-03046-1. View

13.

Xu Y, Lee D, Feng Z, Xu Y, Bu W, Li Y . Breast tumor cell-specific knockout of inhibits cancer cell plasticity, dissemination, and lung metastasis in mice. Proc Natl Acad Sci U S A. 2017; 114(43):11494-11499. PMC: 5664488. DOI: 10.1073/pnas.1618091114. View

14.

Lou Y, Diao L, Parra Cuentas E, Denning W, Chen L, Fan Y . Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. Clin Cancer Res. 2016; 22(14):3630-42. PMC: 4947453. DOI: 10.1158/1078-0432.CCR-15-1434. View

15.

Biddle A, Gammon L, Liang X, Costea D, Mackenzie I . Phenotypic Plasticity Determines Cancer Stem Cell Therapeutic Resistance in Oral Squamous Cell Carcinoma. EBioMedicine. 2016; 4:138-45. PMC: 4776071. DOI: 10.1016/j.ebiom.2016.01.007. View

16.

Colacino J, Azizi E, Brooks M, Harouaka R, Fouladdel S, McDermott S . Heterogeneity of Human Breast Stem and Progenitor Cells as Revealed by Transcriptional Profiling. Stem Cell Reports. 2018; 10(5):1596-1609. PMC: 5995162. DOI: 10.1016/j.stemcr.2018.03.001. View

17.

Luond F, Sugiyama N, Bill R, Bornes L, Hager C, Tang F . Distinct contributions of partial and full EMT to breast cancer malignancy. Dev Cell. 2021; 56(23):3203-3221.e11. DOI: 10.1016/j.devcel.2021.11.006. View

18.

Blasco M, Espuny I, Gomis R . Ecology and evolution of dormant metastasis. Trends Cancer. 2022; 8(7):570-582. DOI: 10.1016/j.trecan.2022.03.002. View

19.

Lytle N, Barber A, Reya T . Stem cell fate in cancer growth, progression and therapy resistance. Nat Rev Cancer. 2018; 18(11):669-680. PMC: 8388042. DOI: 10.1038/s41568-018-0056-x. View

20.

Bonnomet A, Syne L, Brysse A, Feyereisen E, Thompson E, Noel A . A dynamic in vivo model of epithelial-to-mesenchymal transitions in circulating tumor cells and metastases of breast cancer. Oncogene. 2011; 31(33):3741-53. DOI: 10.1038/onc.2011.540. View